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Chronic ischemic heart disease (IHD) is a multifactorial disease with different underlying 
pathogenetic mechanisms. Percutaneous coronary intervention (PCI) is widely used in 
patients with IHD in order to reduce angina recurrence. However, after complete or 
incomplete revascularization procedures, patients may still present anginal symptoms, with a 
detrimental impact on quality of life and prognosis.  
This review summarizes the pathogenic mechanisms and the main challenges encountered in 
the diagnosis and management of post-PCI angina.  
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Ischemic heart disease (IHD) is the leading cause of death and disability for both sexes 
and its prevalence increases in an ageing population [1, 2]. The most frequent, and often the 
first manifestation of IHD, is chronic stable angina that affects approximately 112 million 
people worldwide [3, 4]. Besides pharmacological treatment, percutaneous coronary 
intervention (PCI) is widely used worldwide in IHD patients in order to reduce angina 
recurrence. However, up to 30% of IHD patients with stable angina continue experiencing 
symptoms despite treatment and revascularization procedures [5, 6]. 
Many post-PCI patients are burdened with recurrence of angina, impaired exercise 
capacity and quality of life. In fact, angina prevails over myocardial infarction (MI) and heart 
failure as a reason for impaired quality of life and disability [7]. Greater symptoms of physical 
limitation are strongly predictive of secondary events and poorer survival, independently of 
other factors [7].  
Finally, a common phenomenon is represented by readmissions following PCI. 
Indeed, approximately 25% of patients have unplanned readmissions within 6 months [8]. 
This is due to several factors, 44% of which are cardiac reasons [8]. Interestingly, angina and 
coronary artery disease (CAD) are the biggest contributors to the readmissions due to cardiac 
reasons within 30 days and 1 year after the index PCI [8]. Readmissions after PCI may be 
considered as an adverse outcome for the patient and an unnecessary cost for the healthcare 
system. 
Taking into account all these issues, the present reviews summarize the 
physiopathological mechanisms and the main challenges faced by patients with post-PCI 
angina, with a main focus on relapses of angina symptoms, choice of treatment and its 
optimization.  
 
Recurrence of ischemia and angina in post-PCI patients 
Figure 1 shows the incidence of angina recurrence after PCI in recent randomized 
clinical trials and international registries. In a study including more than 1000 stable angina 
patients evaluated with an exercise test after successful planned PCI, 29% still had an 
abnormal result at 1 month, which reached 31% of cases at 6 months [9]. Accordingly, meta-
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analyses of studies and registries in post-PCI patients demonstrated that, within 1 year after 
successful PCI, the recurrence of angina ranges between 20% and 30% [10] and, within 3 
years, angina persisted or reoccurred in up to 40% of cases, leading to higher healthcare costs 
[11]. Of note, a real-world analysis [11] on the clinical and economic burden associated with 
post-PCI angina recurrence found that total healthcare costs in the first year after the index 
PCI were 1.8 times greater for those with angina or chest pain compared to angina-free 
patients.  
Mechanisms underlying post-PCI angina recurrence are multiple and may include non-
cardiovascular, cardiovascular non-coronary and coronary causes (Fig. 2). These latter may be 
functional and structural.   
 
Functional mechanisms 
Nowadays, functional reasons prevail over the structural ones and microvascular 
dysfunction is found in 64% of angina patients, in the absence of obstructive functionally 
significant epicardial stenosis, with a slightly superior prevalence of female sex [12]. 
Coronary artery vasospasm is also prevalent and is associated with silent myocardial 
ischemia, effort-induced angina and MI [12]. Similarly, myocardial bridging, a congenital 
anomaly in which a segment of a coronary artery presents an intramuscular course under a 
“bridge” of overlying myocardium, may cause vessel compression in systole, resulting in 
hemodynamic changes that may be associated with myocardial ischemia and angina [11]. 
Unfortunately, there is a paucity of data on the rate of functional reasons for ischemia 
along with epicardial stenosis due to an obsolete view that epicardial stenosis was the main 
reason for ischemia and angina. Last but not least, another key pathophysiological mechanism 
underlying symptoms and signs of myocardial ischemia, either in the presence or in the 
absence of an obstructive stenosis, is represented by myocardial cellular metabolic 
disturbances. The latter may cause ischemia and angina, even after removal of significant 
stenosis, further highlighting the need of a paradigm shift in stable IHD [13]. 
For all of these reasons, a functional evaluation is pivotal in PCI patients. There is 
evidence that a functional evaluation of coronary vasculature during PCI is feasible and 
improves a post-PCI drug treatment approach, patients’ symptoms and quality of life [14]. As 
demonstrated by the Fractional flow reserve versus Angiography for Multivessel Evaluation 
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(FAME 2) trial [15], routine measurement of fractional flow reserve (FFR) in patients with 
multivessel CAD who are undergoing PCI with drug-eluting stents significantly reduced the 
rate of the composite endpoint of death, nonfatal MI, and repeat revascularization at 1 year. 
Due to its long-term safety, FFR guidance of multivessel PCI should be the standard of care, 
as also elucidated by the FAME 1 [16]. 
 
Structural mechanisms 
Structural causes of post-PCI angina include in-stent restenosis, stent thrombosis, 
progression of atherosclerotic disease in other coronary segments and incomplete 
revascularization. The incidence of stent thrombosis and in-stent restenosis, the two major 
causes of stent failure, has considerably been reduced in recent years by the introduction of 
new-generation drug-eluting stents [17]. Finally, it was investigated as to whether the type of 
stent influences frequency of angina after PCI. One study found no significant association 
between stent type and angina at 1 year after PCI [18]. Similarly, the A BioreSORBable 
vascular scaffold versus drug-eluting stent in coronary disease (ABSORB) III trial [19] found 
no differences in adverse events at 1 year in CAD patients treated with an everolimus-eluting 
bioresorbable vascular scaffold, as compared with an everolimus-eluting cobalt-chromium 
stent. 
Recurrence of angina due to the progression of coronary atherosclerosis in coronary 
segments different from those treated with PCI, it is also infrequent in the months after the 
procedure (only 5% of major adverse events were related to non-culprit lesions in the 
Providing Regional Observations to Study Predictors of Events in the Coronary Tree 
[PROSPECT] study at 1 year follow up [20]), even though it accounts for approximately half 
of recurrent coronary events. A more common scenario is currently represented by incomplete 
coronary artery revascularization (IR), with incidence rates ranging from 17% to 85% in post-
PCI patients [21, 22]. Such a huge variability is due to differences in study definitions of IR as 
well in the methodology used to analyse its frequency [23]. Regardless the type of 
revascularization, IR significantly impacts patient prognosis, increasing the risk of death, MI, 
repeated revascularization, adverse events and lifestyle-limiting angina [23]. Predictors of IR 
are older age, presence of multiple comorbidities, complex coronary lesions, hyperlipidemia, 
total occlusion and number of diseased vessels [23]. As such, IR is considered a marker of 
complexity that allows the identification of high-risk patients in whom medical therapy is 
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therefore pivotal [24]. Of note, the Ranolazine in patients with Incomplete reVascularisation 
after Percutaneous Coronary Intervention (RIVER-PCI) study [25] aimed to prove the 
efficacy of ranolazine in about 2500 patients with IR after PCI. Although this trial confirmed 
that ischemia-driven events in patients with angina and incomplete revascularization 
following PCI are common (27% over 1.8 years), it failed to prove prognostic benefits of the 
drug in this population [25]. However, there were significant improvements in the frequency 
of angina following PCI in both arms, with no differences between ranolazine vs. placebo at 1 
month (86.6 vs. 85.8, p = 0.62) or 12 months (88.4 vs. 88.5, p = 0.6). Patients with diabetes 
appeared to have a benefit with ranolazine for angina frequency at 6 months (88.3 vs. 85.4, p 
= 0.033; p for interaction = 0.02). This difference, however, dissipated by 12 months (p = 
0.18). Notably, this trial had important limitations since it included a mixed group of patients 
with IR, including untreated chronic total occlusions and diffuse distal disease. In addition, 
the functional significance of untreated CAD was not routinely assessed. 
 
Heart rate control in post-PCI angina patients  
Another key issue in post-PCI angina patients is poor control of heart rate (HR). It is 
well-known that resting HR has an important prognostic role [26], since it independently 
predicts total and cardiovascular mortality in angina patients. Even among patients treated 
with PCI, HR at discharge is a strong predictor of mortality [27]. As such, HR is a component 
of both ischemic and bleeding risk scores. This is due to the role of HR in atherogenesis, 
atherosclerotic plaque formation and progression, and vascular remodelling [28]. Further, HR 
acts as a trigger of ischemia in patients with CAD [29]. Conversely, HR reduction leads to 
clinical benefits and, for this reason, lowering HR is a therapeutic target for angina [30]. 
The latest 2019 European Society of Cardiology guidelines for the management of 
chronic coronary syndromes (CCS) [2] continue recommending target levels of resting HR 
between 55 and 60 bpm. Unfortunately, the latest registries on CCS suggest poor control of 
resting HR in this population. For instance, in the prospeCtive observational LongitudinAl 
RegIstry oF patients with stable coronary arterY disease (CLARIFY) registry [31], including 
more than 32,000 stable angina patients, 50% of the symptomatic angina patients had resting 
HR above 70 bpm, in spite of the beta-blocker therapy, which was taken by 75% of the 
patients. In the same registry, HR above 70 bpm was associated with higher prevalence and 




Choice of anti-anginal drugs/individualized treatment 
Due to the multifactorial origin of IHD, in which different pathogenetic mechanisms 
may co-exist, leading to different clinical pictures with different predominances of symptoms 
over time [32], it is now been ascertained that patients need several anti-angina drugs in order 
to control symptoms, following a patient-oriented approach (Fig. 3). The choice of treatment 
should be related to the mechanisms causing angina, co-morbidities, potential drug-
interactions and tolerability. Thus, an individualized approach to angina treatment, the 
“Diamond” approach, which takes into consideration all these factors, has been proposed (Fig. 
4) [32].  
In particular, current first line anti-anginals, beta-blockers and calcium-channel 
blockers have not proven to have prognostic benefits (except for patients within 1 year after 
MI), as demonstrated by the CLARIFY study [33]. Further, recent meta-analyses found no 
evidence of superiority of one anti-angina class over another in reducing ischemia and angina 
[34]. 
The latest CCS guidelines [2] also acknowledged the lack of evidence of superiority 
amongst the various anti-angina classes, and despite whether the line categorization is kept, 
they confirmed the need of a patient tailored approach, endorsing the early use of the so called 
“second line drugs” along with the ‘first line” drugs, in order to provide adequate treatment 
according to the individual characteristics of the patient. 
For all these reasons, more recent drugs with proven additional anti-anginal efficacy 
should be considered earlier in post-PCI symptomatic patients, along with the so called “first-
line” anti-anginal drugs, given that the categorization of an antianginal drug of first or second 
line is not confirmed [35]. Thus, ivabradine, trimetazidine and ranolazine should be 
considered, as described elsewhere [32]. 
Briefly, ivabradine was found to reduce symptoms and improve quality of life in a 
post-hoc analysis on angina patients with a history of revascularization, who remained 
symptomatic in spite of an individually optimized dose of a beta blocker [36]. A recent study 
[37] in patients with residual ischemia after PCI, demonstrated ivabradine benefits on 
significant reduction of HR, lower incidence of angina during the stress test and 
improvements in functional capacity. 
7 
 
As for trimetazidine, it has proven benefits in patients with recurrent angina after PCI 
in spite of beta-blocker therapy such as preventing recurrence of angina, reducing restenosis, 
with a good safety profile [38]. 
Yet, it should be noted that some of these studies are single-center or open-label. The 
efficAcy and safety of Trimetazidine in patients with angina pectoris having been treated by 
Percutaneous Coronary Intervention (ATPCI) trial [39], was a randomized, multicenter, 
placebo controlled trial on more than 6000 post-PCI patients, which failed to demonstrate 
significant benefits of trimetazidine vs placebo on the  primary efficacy endpoint, a composite 
of cardiac death, hospital admission for a cardiac event, recurrence or persistence of angina 
requiring other antianginal drugs or recurrence or persistence of angina requiring a coronary 
angiography.  However, it is important to underline that the ATPCI study was not designed to 
evaluate antianginal properties of trimetazidine since patients included were asymptomatic 
and at low risk [39]. 
 
Optimization of anti-angina therapy  
Despite its importance, anti-anginal therapy is still often neglected in post-PCI angina 
patients. In the Clinical Outcomes Utilizing Revascularization and Aggressive Drug 
Evaluation (COURAGE) trial [40], only 60% of the patients were on optimized medical 
therapy after PCI. In the Suivi d’une cohorte de patients COROnariens stables en région 
NORd-Pas-de-Calais (CORONOR) registry [41], the average number of anti-anginal drugs in 
post-PCI patients was rather low (mean: 1,4). In the recent International Study of 
Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) trial 
[42], optimal medical therapy was prescribed, and risk factors control was obtained in more 
than 5000 patients with moderate to severe ischemia. The results demonstrated no superiority 
of PCI as an initial strategy on top of optimized medical therapy over optimized medical 
therapy alone. However, in the overall trial population, which included 35% of participants 
without angina at baseline, patients randomly assigned to the invasive strategy had greater 
improvement in angina-related health status than those assigned to the conservative strategy. 
The modest mean differences favoring the invasive strategy in the overall group reflected 
minimal differences among asymptomatic patients and larger differences among patients who 
had had angina at baseline [43]. 
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It is even more striking that, in a study following post primary PCI patients [44], 
among the 30% who reported angina within 6 weeks after the procedure, 68% remained 
treated only with beta-blocker, and did not receive a second anti-anginal drug.  
Another main issue observed in clinical practice is the de-escalation of antianginal 
medications after PCI. There is evidence that down-titration is associated with an increased 
risk of angina recurrence and worsening of health status, particularly among patients with 
incomplete revascularization [23]. Interestingly, in the aforementioned RIVER-PCI study 
[25], 67% of the patients were taking 0–1 anti-ischemic/angina drug in spite of the incomplete 
revascularization in parallel with the 44% reporting daily or weekly angina after the 
procedure. 
The STable Coronary Artery Diseases RegisTry (START) study [45], a prospective, 
observational, nationwide study aimed to evaluate the presentation, management, treatment 
and quality of life of patients with stable CAD, revealed that treatment is still suboptimal in 
patients with angina. Although angina patients more frequently received antianginal drugs 
compared to patients without angina, the combinations of angina relief drugs were rarely 
employed.  
Such an inadequate post-PCI anti-angina treatment could be due to different reasons. 
First, from a socio-psychological point of view, the desire of both healthcare professionals 
and patients to believe that the problem is solved may lead to some kind of inertia. Second, 
there are reasons linked to the healthcare system, such as the lack of systematic monitoring of 
symptoms after PCI. A German study [46] demonstrated that 10% of ambulatory cardiologists 
did not ask patients about symptoms after PCI and 19% did not consider initiating drug 
therapy in angina patients with overruled significant coronary stenosis. 
Third, a discrepancy between patient and doctor perceptions of burden of the disease 
may very often lead to under-recognition of angina. Up to 60% of the angina cases are not 
recognized by physicians in ambulatory practice, leading to lower rate of angina treatment up-
titration [47]. 
A recent multinational European physician survey [48], on 659 general practitioners 
and cardiologists evaluating more than 1900 stable angina patients, found a striking 
underestimation of the disease burden, especially in elderly, women, and those patients with a 
long-standing diagnosis (more than 2 years). Moreover, patients who previously had a PCI 
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had more severe stable angina, despite more intense medical treatment, than patients without 
previous PCI. 
All these data demonstrate that close monitoring of stable angina patients and 
optimization of anti-angina therapy, even after a successful PCI, is mandatory in order to 
adequately treat symptoms and alleviate the disease burden.  
 
Conclusions 
Recurrence of angina is a frequent and still neglected condition after contemporary 
PCI. History of symptoms, clinical examination and functional imaging are essential to guide 
healthcare professionals in the search for possible underlying reasons for angina persistence 
and relapses in post-PCI patients. Optimizing anti-angina therapy is a necessary step, 
especially in absence of regional wall motion abnormalities.  
Thus, an efficacious and repeated monitoring may help improve post-PCI management 
in clinical practice and, also, may prevent an excessive and unnecessary use of PCI before 
optimizing medical therapy. 
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Figure 1. Incidence of recurrent post-percutaneous coronary intervention angina according to 
main randomized clinical trials (*) and Registries (**); BVS — bioresorbable vascular 
scaffold; EES — everolimus-eluting stent; FFR — fractional flow reserve. 
Figure 2. Cardiovascular and non-cardiovascular mechanisms of post-percutaneous coronary 
intervention angina recurrence; COPD — chronic obstructive pulmonary disease; HCM — 
hypertrophic cardiomyopathy; LV — left ventricle; MI — myocardial infarction. 
Figure 3. Flowchart of stable angina pectoris treatment; HR — heart rate. 
Figure 4. Combinations among classes of antianginal drugs according to the Diamond 
approach; *dihydropyridines. 




